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arotid ultrasound has been used as a research tool in
pidemiology and in clinical trials of cardiovascular disease
nterventions for nearly 3 decades. Since 2000, 7 guidelines
r consensus statements have recommended measuring
arotid intima-media thickness (CIMT) and/or carotid
laque detection as clinical tools to assist with cardiovascular
isease risk prediction (1). In 2008, the American Society of
chocardiography (ASE) published a consensus statement
n the clinical use of carotid ultrasound for cardiovascular
isease risk assessment (1). This statement addressed stan-
ardization of imaging and measurement protocols as well
s training, instrumentation, and quality control. It also
efined appropriate patients for whom carotid ultrasound
ould be considered as a clinical tool for risk prediction.
See page 1600
However, the United States Preventive Services Task
orce (USPSTF) recently recommended against measure-
ent of anatomic markers of atherosclerosis, including
IMT (2,3). The USPSTF based its negative recommen-
ation regarding CIMT, in part, on the absence of specific
ata regarding the independent predictive value of CIMT
or patients at intermediate coronary heart disease (CHD)
isk and on concerns about this test’s ability to reclassify
uch patients into lower or higher risk categories, therefore
ltering their clinical management (2,3). They also criticized
he evidence base supporting CIMT as a risk prediction tool
ince some studies associating CIMT with CHD risk
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onditions, were of relatively short duration, and had few
HD events.
arotid Ultrasound as a
isk Prediction Tool—in Context
he report by Nambi et al. (4) in this issue of the Journal
rovides the best evidence, to date, demonstrating the
bility of carotid ultrasound data to improve CHD risk
rediction. These findings have direct clinical implications
or the use of CIMT and carotid plaque detection in CHD
isk prediction, and they address several of the USPSTF’s
oncerns (2,3). Nambi et al. (4) studied 13,145 subjects who
ere free of prevalent CHD or stroke at the inception of the
RIC (Atherosclerosis Risk In Communities) study (4).
fter a mean of 15.1 years follow-up, participants had 1,812
HD events, the majority of which were “hard” events such
s coronary death or myocardial infarction. The authors
valuated the additional predictive value of CIMT, plaque
resence, or both carotid ultrasound findings to CHD risk
rediction. They found that the area under the receiver-
perating characteristic curve (AUC) for traditional risk
actor prediction of CHD events (0.742) was significantly
ncreased by the addition of increased CIMT (0.750) or
arotid plaque presence (0.751), and that the combination
f risk factors, CIMT, and plaque yielded the highest AUC
0.755) (4). These findings support the ASE’s recommen-
ation of combining CIMT and carotid plaque data for
ptimal risk prediction (1).
For men, adding carotid plaque presence to models that
ncorporated CIMT did not improve discrimination,
hereas for women, adding CIMT to models that included
laque was not helpful (4). Because atherosclerosis is rela-
ively uncommon among middle-aged women, the authors
uggested that its presence indicated more advanced athero-
clerosis and therefore higher CHD risk (4). This is a
lausible explanation, consistent with the observation that
arotid plaque presence generally is more predictive of
HD risk than CIMT (1), and that coronary calcification,
marker of more advanced atherosclerosis than increased
IMT, is more predictive of CHD (but not stroke) (5).
owever, the apparent sex difference in risk prediction also
ay reflect the carotid imaging protocol, which included
easurement of CIMT not only in the common carotid
rtery, but also in the bulb and internal carotid artery
egments, where plaques form earliest. Nearly two-thirds of
atients with increased CIMT had carotid plaques, so it is
ikely that the predictive information contained in the
IMT measurements overlapped with plaque presence (4).
he fact that bulb and internal CIMT contain redundant
nformation with carotid plaque presence explains why the
reatest increment in predictive accuracy was seen when
ither CIMT or plaque was added to the traditional risk
actor model, but adding the other carotid ultrasound
easure only increased its predictive value modestly. It also
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n the common carotid artery must incorporate scanning
he remaining segments of the carotid arteries for plaques,
o avoid missing “upstream” advanced atherosclerosis (1).
Although the 0.008 to 0.013 increments in AUC
chieved using the carotid ultrasound data may seem small,
hey are on the same order of magnitude as the individual
ontributions of smoking status and systolic blood pressure
o the Reynold’s Risk Score for women, and greater than the
ontributions of lipids, family history, and high-sensitivity
-reactive protein (6). Indeed, after age and sex are con-
idered in almost any CHD predictive model, additional
isk factors contribute little on an individual basis, but are
ery important when considered in aggregate. The limita-
ions of the AUC as the sole descriptor of a predictive
odel’s accuracy are well known (7).
Of greater importance to the clinician are indices of
eclassification that address how often exceeding a threshold
or a risk marker correctly reclassifies a person’s predicted
isk, and by extension, alters the clinical management. For
he carotid ultrasound data presented by Nambi et al. (4),
he conclusions are clear. Large numbers of persons in the
ntermediate-risk classifications were reclassified when
IMT and plaque data were considered. Indeed, 37.5% of
atients in the 5% to 10% CHD risk stratum (based on risk
actors) and 38.3% of patients in the 10% to 20% risk
tratum were reclassified when carotid ultrasound data were
onsidered, with plaque presence being more important
han increased CIMT among women (4). Adding either
IMT or carotid plaque presence to traditional risk factors
ed to net clinical reclassification indices of 16.7% and
7.7%, respectively; 21.7% when used together (4). These
ndings demonstrate that ultrasound findings of increased
IMT or plaque improve CHD risk prediction among
atients at intermediate risk—the very patients for whom
isk prediction and subsequent medical management are
ost challenging. The magnitude of reclassification using
arotid ultrasound findings is similar to or greater than that
bserved with the Reynold’s Risk Score (vs. the Framing-
am Risk Score) and its individual components, including
igh-sensitivity C-reactive protein (6,8).
Finally, it must be recognized that the majority of
eclassified patients moved into a lower risk stratum, rather
han a higher risk stratum, mitigating some of the concern
hat testing uncovers disease that may not need to be
reated, and raising the intriguing hypothesis that carotid
ltrasound could be used to identify persons at lower than
pparent risk who might be candidates for less intensive
nterventions.
therosclerosis Imaging—the Bigger Picture
f course, the clinical utility of carotid ultrasound or any
therosclerosis imaging test for CHD risk prediction cannot
e demonstrated by observational studies, no matter how
arge or well conducted they may have been. Demonstratinghe utility of these tests is more than an issue of mathemat-
cs and requires more than elegant statistical analyses—it
equires outcomes research. To convincingly demonstrate
he value of atherosclerosis imaging will require prospective,
andomized studies comparing a strategy of imaging-guided
isk factor modification to risk factor modification alone.
his is the standard to which pharmacological agents are
eld; we should expect no less regarding use of imaging tests
hat can profoundly affect patient management and health
are costs. In this regard, randomized data showing the
fficacy of any atherosclerosis imaging strategy are scant.
he best data are from the METEOR (Measuring Effects
n Intima-Media Thickness: An Evaluation of Rosuvasta-
in) Study, a prospective multicenter clinical trial of middle-
ged adults at low to intermediate CHD risk who would not
ave qualified for lipid-lowering therapy but who had
ncreased CIMT (9). Subjects randomly assigned to statins,
s opposed to placebo, had less progression of CIMT; the
ifference in CIMT progression rates was similar to that
bserved in secondary prevention trials of statin therapy that
ere associated with a reduction in CHD events (9,10).
In summary, the report by Nambi et al. (4) provides clear
nswers to several concerns expressed about CIMT imaging
y the USPSTF (2,3), and their findings validate the recent
onsensus statement recommendations for appropriate pa-
ient selection for use of carotid cardiovascular disease risk
rediction (1). The National Cholesterol Education Pro-
ram Adult Treatment Panel IV should carefully consider
hese findings in their deliberations about use of carotid
ltrasound and CHD risk assessment. This paper closes the
iscussion about the incremental value of carotid ultrasound
or CHD risk prediction in patients at intermediate risk,
hus opening the door for outcomes research studies that are
equired to determine if atherosclerosis imaging truly is as
elpful as its proponents believe.
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